Aegerion Pharmaceuticals Inc. (AEGR): Broadfin Capital Raises Its Stake Ahead of Merger

Page 5 of 10 – SEC Filing

CUSIP No.	00767E102

Item 1.

Security and Issuer.

	This statement on Schedule 13D (the “Schedule 13D”) relates to the Common Stock, $.001 par value (the “Common Stock”), of Aegerion Pharmaceuticals, Inc., a Delaware corporation with its principal executive offices located at One Main Street, Suite 800, Cambridge, Massachusetts 02142 (the “Issuer”).

Item 2.

Identity and Background.

(a)-(c), (f)

This Schedule 13D is being filed jointly by (i) Broadfin Capital, LLC, a Delaware limited liability company, (ii) Broadfin Healthcare Master Fund, Ltd., an exempted company incorporated and existing under the laws of the Cayman Islands, and (iii) Kevin Kotler, a United States citizen (collectively, the “Reporting Persons”). The principal business address of the Reporting Persons is 300 Park Avenue, 25th Floor, New York, New York 10022. Kevin Kotler is the managing member of Broadfin Capital, LLC, an investment management firm that serves as the investment manager to Broadfin Healthcare Master Fund, Ltd.  The principal business of Broadfin Healthcare Master Fund, Ltd. is purchasing, holding and selling securities for investment purposes.

	(d)	None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
	(e)	None of the Reporting Persons has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws.